A number of anti-diabetic agents, such as thiazolidinedione insulin sensitizers, glucagon-like peptide 1 (GLP1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, are studied in NAFLD clinical trials by increasing insulin sensitivity, reducing bodyweight, and improving systemic metabolism [4,15,16]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.